Biodesix closes on $5.2 million, plans to raise another $5 million
BOULDER — Biodesix Inc., a life-sciences company that does molecular diagnostics tests, has closed on $5.28 million in capital.
The company raised the funds through convertible promissory notes and equity securities issuable upon the conversion of the notes, according to a Form D filed with the U.S. Securities and Exchange Commission on May 8.
CEO David Brunel told BizWest that the company plans to close on another $5 million in funding in the next few weeks.
SPONSORED CONTENT
Biodesix, which makes blood-based molecular tests, is raising the capital because of its continuing growth, Brunel said.
BOULDER — Biodesix Inc., a life-sciences company that does molecular diagnostics tests, has closed on $5.28 million in capital.
The company raised the funds through convertible promissory notes and equity securities issuable upon the conversion of the notes, according to a Form D filed with the U.S. Securities and Exchange Commission on May 8.
CEO David Brunel told BizWest that the company plans to close on another $5 million in funding in the next few weeks.
Biodesix, which makes blood-based molecular tests, is raising the capital because of its continuing growth, Brunel said.…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
